Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Report

Global and Region Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 30, 2022
  • PAGES：185
  • REPORT CODE：GMM897869
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx)market, defines the market attractiveness level of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) industry, describes the types of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market, the applications of major players and the market size, and deeply analyzes the current situation of the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market and the development prospects and opportunities of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market in Chapter 13.

    By Player:

    • Leica Biosystems Nussloch GmBH

    • Thermo Fisher Scientific Inc

    • GE Healthcare

    • Qiagen NV

    • Pfizer

    • F Hoffman La Roche

    • Foundation Medicine

    • Agilent Technologies

    By Type:

    • PCR

    • In-situ Hybridization

    • Immunohistochemistry

    • Sequencing

    • Others

    By End-User:

    • Oncology

    • Neurological Disorders

    • Cardiovascular Disease

    • Immunological Disorders

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Analysis and Outlook to 2022

    • 7.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption (2017-2022)

    • 7.2 United States Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption (2017-2022)

    • 7.3 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption (2017-2022)

    • 7.4 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption (2017-2022)

    • 7.5 Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption (2017-2022)

    • 7.6 India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption (2017-2022)

    • 7.7 South Korea Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption (2017-2022)

    8 Region and Country-wise Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Analysis and Outlook to 2028

    • 8.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Forecast (2022-2028)

    • 8.2 United States Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Forecast (2022-2028)

    • 8.3 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Forecast (2022-2028)

    • 8.4 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Forecast (2022-2028)

    • 8.5 Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Forecast (2022-2028)

    • 8.6 India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Forecast (2022-2028)

    • 8.7 South Korea Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Forecast (2022-2028)

    9 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Outlook by Types and Applications to 2022

    • 9.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global PCR Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global In-situ Hybridization Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Immunohistochemistry Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Sequencing Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Oncology Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Neurological Disorders Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Cardiovascular Disease Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Immunological Disorders Consumption and Growth Rate (2017-2022)

      • 9.2.5 Global Others Consumption and Growth Rate (2017-2022)

    10 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Outlook by Types and Applications to 2028

    • 10.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global PCR Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global In-situ Hybridization Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Immunohistochemistry Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Sequencing Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.5 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Oncology Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Neurological Disorders Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Cardiovascular Disease Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.4 Global Immunological Disorders Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.5 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Competitive Analysis

    • 14.1 Leica Biosystems Nussloch GmBH

      • 14.1.1 Leica Biosystems Nussloch GmBH Company Details

      • 14.1.2 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Service

    • 14.2 Thermo Fisher Scientific Inc

      • 14.2.1 Thermo Fisher Scientific Inc Company Details

      • 14.2.2 Thermo Fisher Scientific Inc Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Thermo Fisher Scientific Inc Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Service

    • 14.3 GE Healthcare

      • 14.3.1 GE Healthcare Company Details

      • 14.3.2 GE Healthcare Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 GE Healthcare Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Service

    • 14.4 Qiagen NV

      • 14.4.1 Qiagen NV Company Details

      • 14.4.2 Qiagen NV Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Qiagen NV Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Service

    • 14.5 Pfizer

      • 14.5.1 Pfizer Company Details

      • 14.5.2 Pfizer Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Pfizer Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Service

    • 14.6 F Hoffman La Roche

      • 14.6.1 F Hoffman La Roche Company Details

      • 14.6.2 F Hoffman La Roche Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 F Hoffman La Roche Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Service

    • 14.7 Foundation Medicine

      • 14.7.1 Foundation Medicine Company Details

      • 14.7.2 Foundation Medicine Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Foundation Medicine Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Service

    • 14.8 Agilent Technologies

      • 14.8.1 Agilent Technologies Company Details

      • 14.8.2 Agilent Technologies Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Agilent Technologies Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx)

    • Figure Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Picture

    • Table Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption by Country (2017-2022)

    • Figure United States Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption and Growth Rate (2017-2022)

    • Table Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption and Growth Rate (2017-2022)

    • Figure China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption and Growth Rate (2017-2022)

    • Figure Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption and Growth Rate (2017-2022)

    • Figure India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption and Growth Rate (2017-2022)

    • Figure South Korea Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption and Growth Rate (2017-2022)

    • Figure Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Forecast by Country (2022-2028)

    • Figure United States Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global PCR Consumption and Growth Rate (2017-2022)

    • Figure Global In-situ Hybridization Consumption and Growth Rate (2017-2022)

    • Figure Global Immunohistochemistry Consumption and Growth Rate (2017-2022)

    • Figure Global Sequencing Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Oncology Consumption and Growth Rate (2017-2022)

    • Figure Global Neurological Disorders Consumption and Growth Rate (2017-2022)

    • Figure Global Cardiovascular Disease Consumption and Growth Rate (2017-2022)

    • Figure Global Immunological Disorders Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global PCR Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global In-situ Hybridization Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Immunohistochemistry Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Sequencing Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Oncology Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Neurological Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Cardiovascular Disease Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Immunological Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Export by Region (Top 5 Countries) (2017-2028)

    • Table Leica Biosystems Nussloch GmBH (Foundation Year, Company Profile and etc.)

    • Table Leica Biosystems Nussloch GmBH Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Leica Biosystems Nussloch GmBH Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Service

    • Table Thermo Fisher Scientific Inc (Foundation Year, Company Profile and etc.)

    • Table Thermo Fisher Scientific Inc Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Thermo Fisher Scientific Inc Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Service

    • Table GE Healthcare (Foundation Year, Company Profile and etc.)

    • Table GE Healthcare Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales, Price, Value and Gross Profit (2017-2022)

    • Table GE Healthcare Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Service

    • Table Qiagen NV (Foundation Year, Company Profile and etc.)

    • Table Qiagen NV Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Qiagen NV Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Service

    • Table Pfizer (Foundation Year, Company Profile and etc.)

    • Table Pfizer Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Service

    • Table F Hoffman La Roche (Foundation Year, Company Profile and etc.)

    • Table F Hoffman La Roche Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales, Price, Value and Gross Profit (2017-2022)

    • Table F Hoffman La Roche Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Service

    • Table Foundation Medicine (Foundation Year, Company Profile and etc.)

    • Table Foundation Medicine Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Foundation Medicine Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Service

    • Table Agilent Technologies (Foundation Year, Company Profile and etc.)

    • Table Agilent Technologies Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Agilent Technologies Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US